Latest News-Harbour Biomed Mediaroom_Page

Harbour BioMed Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Oct. 13, 2022 /PRNewswire/ -- Harbour B...

2022-10-13 19:05 1778

Harbour BioMed Announces First Subject Dosed in Phase I Study of Next-Gen Anti-TSLP Fully Human Monoclonal Antibody

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Sept. 27, 2022 /PRNewswire/ -- Harbour ...

2022-09-27 21:40 1672

Harbour BioMed to Announce 2022 Interim Results on August 31, 2022

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 9, 2022 /PRNewswire/ -- Harbour Bi...

2022-08-09 15:00 2081

PNAS Published Preclinical Results of Harbour BioMed's Next-Generation Fully Human Heavy-chain Antibody Porustobart

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 8, 2022 /PRNewswire/ -- Harbour Bi...

2022-08-08 17:43 2205

PNAS Published Preclinical Results of Harbour BioMed's Next-Generation Fully Human Heavy-chain Antibody Porustobart

Harbour BioMed Announces IND Clearance for B7H4x4-1BB Bispecific Antibody by the U.S. Food and Drug Administration

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, June 27, 2022 /PRNewswire/ -- Harbour B...

2022-06-27 19:04 2728

Harbour BioMed Announces IND Approval for B7H4x4-1BB Bispecific Antibody

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 8, 2022 /PRNewswire/ --Harbour ...

2022-06-08 18:11 1920

Harbour BioMed Reports the Latest Progress of Next-Generation Fully Human Heavy-chain Antibody HBM4003 with Unique Treg Depletion Mechanism

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 1, 2022 /PRNewswire/ -- Harbour...

2022-06-01 21:24 2867

Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 25, 2022 /PRNewswire/ -- Harbour...

2022-05-25 17:42 2613

Harbour BioMed to Present the Latest Progress of Next-Generation Anti-CTLA-4 Antibody HBM4003 at 2022 ASCO Annual Meeting

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 10, 2022 /PRNewswire/ -- Harbour...

2022-05-10 16:54 3009

Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 5, 2022 /PRNewswire/ -- Harbour ...

2022-05-06 08:00 2334

Harbour BioMed Appoints Dr. Humphrey Gardner as Chief Medical Officer

CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands, April 13, 2022 /PRNewswire/ -- Harbour ...

2022-04-14 08:46 1937

Harbour BioMed Announces Global Out-License Agreement with AstraZeneca for CLDN18.2xCD3 Bispecific Antibody HBM7022

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, April 6, 2022 /PRNewswire/ -- Harbou...

2022-04-07 09:09 2052

Harbour BioMed Announces Poster Presentation on the Novel Bispecific Antibody PD-L1xCD40 at Upcoming American Association for Cancer Research (AACR) Annual Meeting

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, April 6, 2022 /PRNewswire/ -- Harbour B...

2022-04-06 15:04 2782

Harbour BioMed Reports Full Year 2021 Financial Results: Empower Value Creation with Global Innovation Capabilities

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, March 24, 2022 /PRNewswire/ --Harbou...

2022-03-25 10:22 3429

Harbour BioMed Announces IND Approval for Next-Gen Anti-TSLP Fully Human Monoclonal Antibody

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Feb. 21, 2022 /PRNewswire/ -- Harbou...

2022-02-21 20:29 2386

Harbour BioMed Announces Dosing of First Patient in Combination Therapy Phase Ib/IIa Trial of Next-Generation Anti-CTLA-4 Antibody

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Harbou...

2022-01-24 15:39 2022

Harbour BioMed Announces Dosing of First Patient of Two Phase I Trials for Next-Generation Anti-CTLA-4 Antibody HBM4003

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Jan. 4, 2022 /PRNewswire/ -- Harbour...

2022-01-04 17:28 2207

Harbour BioMed Announces Dosing of First Patient of Batoclimab Phase II Trial in Patients with Thyroid Eye Disease

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Oct. 19, 2021 /PRNewswire/ -- Harbou...

2021-10-19 17:52 2219

Harbour BioMed Announces Dosing of First Patient of Batoclimab Phase III Trial in Patients with Generalized Myasthenia Gravis

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 27, 2021 /PRNewswire/ -- Harbo...

2021-09-27 21:03 4974

Harbour BioMed Announces Phase I Study Positive Results on Next-Generation Anti-CTLA-4 Antibody HBM4003

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 13, 2021 /PRNewswire/ -- Harbo...

2021-09-13 14:34 3169